<head>
    <script type="text/javascript" src="/TemplatePackage/contrib/libs/jquery/jquery-1.11.3.min.js"></script>
</head>

<div id="testEndPoint">Test endpoint node which points to <a href='#' onclick='event.preventDefault(); nodeHistory.push(new NodeHistory(currentQuestionNumber, null)); loadNode(3);'>Node 3</a></div>
<div id="armAInitialrRTPCR">
    <strong>Action needed:</strong>
    <ul>
    <li>Collect serum and urine specimens. Order rRT-PCR test.</li>
        <li>ACOG recommends storing additional samples for further testing that might be needed.
            <ul>
                <li>Per the ACOG Practice Advisory on Zika Virus: “Not all laboratories have the capacity to perform
                    confirmatory follow up testing automatically (as a "reflex") or to forward specimens to another testing
                    laboratory. Because of this, providers should store additional samples for further testing if needed.”
                </li>
            </ul>
        </li>
    </ul>
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
    <br /><br />
    <strong>Follow-up action will be needed. Return to this tool for help interpret the test results and determine if
        additional testing might be needed to confirm or rule out Zika virus infection. </strong>
</div>
<div id="zikaAndDengueIgMTests">
    <strong>Action needed:</strong>
    <ul>
        <li>Collect serum and urine specimens. Order Zika virus IgM test.</li>
        <li>ACOG recommends storing additional samples for further testing that might be needed.
            <ul>
                <li>Per the ACOG Practice Advisory on Zika Virus: “Not all laboratories have the capacity to perform
                    confirmatory follow up testing automatically (as a "reflex") or to forward specimens to another testing
                    laboratory. Because of this, providers should store additional samples for further testing if needed.”
                </li>
            </ul>
        </li>
    </ul>
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
    <br /><br />
    <strong>Follow-up action will be needed. Return to this tool for help interpreting the test results and determining if
        additional testing might be needed to confirm or rule out Zika virus infection. </strong>
</div>
<div id="clinicalManagementOver12weeks">
    <strong>Clinical Management: </strong>For symptomatic and asymptomatic pregnant women with possible Zika virus
    exposure who seek care >12 weeks after symptom onset or possible exposure, IgM antibody testing might be
    considered. If fetal abnormalities are present, rRT-PCR testing should also be performed on maternal serum and
    urine. However, a negative IgM antibody test or rRT-PCR result >12 weeks after symptom onset or possible exposure
    does not rule out recent Zika virus infection because IgM antibody and viral RNA levels decline over time.
    Given the limitations of testing beyond 12 weeks after symptom onset or possible exposure, serial fetal
    ultrasounds should be considered.
    <br /><br />
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspected
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
</div>
<div id="zikaIgMTest">
    <strong>Action needed:</strong>
    <ul>
        <li>Collect serum and urine specimens. Order Zika virus IgM antibody test.</li>
        <li>ACOG recommends storing additional samples for further testing that might be needed.
            <ul>
                <li>Per the ACOG Practice Advisory on Zika Virus: “Not all laboratories have the capacity to perform
                    confirmatory follow up testing automatically (as a "reflex") or to forward specimens to another testing
                    laboratory. Because of this, providers should store additional samples for further testing if needed.”
                </li>
            </ul>
        </li>
    </ul>
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
    <br /><br />
    <strong>Follow-up action will be needed. Return to this tool for help interpret the test results and determine if
        additional testing might be needed to confirm or rule out Zika virus infection. </strong>
</div>
<div id="lowRiskOfExposure">
    <strong>Interpretation:</strong> Based on your assessment of possible exposure, your patient is at low risk for
    travel-associated mosquito transmission or sexual transmission of Zika. However, if your patient has signs or
    symptoms consistent with Zika virus disease and other risk factors for exposure, talk to your health department
    for individualized guidance.
    <br /><br />
    <strong>Prevention messages:</strong>
    <br />
    <strong>Pregnant women</strong>
    <ul>
        <li>Do not travel to <a target="_blank" href="http://www.cdc.gov/zika/geo/active-countries.html">
            areas with Zika</a>.
        </li>
        <li>If you must travel, talk to your doctor or other healthcare provider first and take steps to
            <a target="_blank" href="http://www.cdc.gov/zika/prevention/prevent-mosquito-bites.html">
                prevent mosquito bites</a> and
            <a target="_blank" href="http://www.cdc.gov/zika/prevention/protect-yourself-during-sex.html">
                prevent sexual transmission</a> during your trip.
        </li>
        <li>
            If your sex partner travels to an area with Zika,
            <a target="_blank" href="http://www.cdc.gov/zika/prevention/protect-yourself-during-sex.html">
                protect yourself from getting Zika during sex</a>.
        </li>
    </ul>
</div>
<div id="clinicalManagementPresentingForCareIn3rdTrimesterAsymptomaticPregnantWomenAtOngoingRiskForExposure">
    <strong>Interpretation: </strong>For asymptomatic pregnant women at ongoing risk for Zika virus exposure who enter
    prenatal care after the 1<sup>st</sup> or 2<sup>nd</sup> trimester, monitor for signs and symptoms consistent
    with Zika virus disease. Follow <a href="#" onclick="event.preventDefault();
    nodeHistory.push(new NodeHistory(currentQuestionNumber, null));loadNode(21);">clinical management</a> for those
26    exposed to Zika virus and consider testing if fetal abnormalities consistent with congenital Zika virus syndrome
    are present. Placental testing can be considered.
    <br /><br />
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
</div>
<div id="prenatalClinicalManagement3rdTrimester">
    <strong>Recommendations for prenatal management:</strong>
    <ul>
        <li>
            Consider serial ultrasounds <strong>every 3-4 weeks</strong> to assess fetal anatomy and growth. Fetal
            abnormalities consistent with congenital Zika virus syndrome include microcephaly, intracranial
            calcifications, ventriculomegaly, arthrogryposis, and abnormalities of the corpus callosum, cerebrum,
            cerebellum, and eyes.
        </li>
        <li>
            Notify state, tribal, local, or territorial health department staff or CDC registry staff of adverse
            events (e.g., birth defects, pregnancy losses).
        </li>
    </ul>
</div>
<div id="clinicalManagementRecentZikaInfection"> <!--No longer used -->
    <strong>Interpretation of Test Result:</strong> Test results suggest recent maternal Zika virus infection. For
    clinical management recommendations, answer <a href="#" onclick="event.preventDefault();
    nodeHistory.push(new NodeHistory(currentQuestionNumber, null));loadNode(26);">this question</a>.
</div>
<div id="clinicalManagementRecentFlavivirusInfectionNOS"> <!--No longer used -->
    <strong>Interpretation of Test Result:</strong> Test results suggest recent maternal flavivirus infection, but
    the specific virus cannot be identified. For clinical management recommendations, answer <a href="#"
    onclick="event.preventDefault(); nodeHistory.push(new NodeHistory(currentQuestionNumber, null));loadNode(26);">
    this question</a>.
</div>
<div id="prenatalClinicalManagementRecentZikaInfectionOrFlavivirusNOS">
    <strong>Recommendations for prenatal management:</strong>
    <ul>
        <li>
            Consider serial ultrasounds <strong>every 3-4 weeks</strong> to assess fetal anatomy and growth. Fetal
            abnormalities consistent with congenital Zika virus syndrome include microcephaly, intracranial
            calcifications, vetriculomegaly, arthrogryposis, and abnormalities of the corpus callosum, cerebrum,
            cerebellum, and eyes.
        </li>
        <li>
            Decisions regarding amniocentesis should be individualized for each clinical circumstance.
        </li>
        <li>
            Notify state, tribal, local, or territorial health department staff or CDC registry staff of adverse
            events (e.g., birth defects, pregnancy losses).
        </li>
    </ul>
    <strong>Action needed: Zika virus disease is a nationally notifiable condition. Your patient meets criteria for
        reporting to the
        <a target="_blank" href="http://www.cdc.gov/zika/hc-providers/registry.html">US Zika Pregnancy Registry</a>.
    </strong> Report information about pregnant women with laboratory evidence of Zika virus to your state, tribal,
    local, or territorial health department.
    <ul>
        <li>
            If you are a healthcare provider or health department and you have questions about the registry, please
            <a href="mailto:ZikaMCH@cdc.gov">email</a> or call 770-488-7100 and ask for the Zika Pregnancy
            Hotline.
        </li>
    </ul>
</div>
<div id="postnatalClinicalManagementRecentZIKVInfectionOrFlavivirusNOSLiveBirth">
    <strong>Recommendations for postnatal management of live births:</strong>
    <ul>
        <li>
            Infant samples should be tested for Zika virus rRT-PCR and Zika IgM antibodies. If cerebrospinal fluid is
            obtained for other reasons, it can also be tested.
        </li>
        <li>
            Zika virus rRT-PCR and immunohistochemical staining of umbilical cord and placenta is recommended in
            certain situations. Pathology guidance for collection and submission of fetal tissues for Zika virus
            testing for detailed information on recommended specimen types can be found here:
            <br />
            <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-tissues.html">
                http://www.cdc.gov/zika/laboratories/test-specimens-tissues.html
            </a>
        </li>
        <li>
            Notify state, tribal, local, or territorial health department staff or CDC registry staff of adverse
            events (e.g., birth defects, perinatal or infant deaths).
        </li>
    </ul>
    <strong>Action needed: Zika virus disease is a nationally notifiable condition. Your patient meets criteria for
        reporting to the
        <a target="_blank" href="http://www.cdc.gov/zika/hc-providers/registry.html">US Zika Pregnancy Registry</a>.
    </strong> Report information about pregnant women with laboratory evidence of Zika virus to your state, tribal,
    local, or territorial health department.
    <ul>
        <li>
            If you are a healthcare provider or health department and you have questions about the registry, please
            <a href="mailto:ZikaMCH@cdc.gov">email</a> or call 770-488-7100 and ask for the Zika Pregnancy
            Hotline.
        </li>
    </ul>
</div>
<div id="postnatalClinicalManagementRecentZIKVInfectionOrFlavivirusNOSPregnancyLoss">
    <strong>Recommendations for postnatal management of pregnancy losses:</strong>
    <ul>
        <li>
            Zika virus rRT-PCR and immunohistochemical staining of fetal tissues is recommended. Pathology guidance
            for collection and submission of fetal tissues for Zika virus testing can be found here:
            <br />
            <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-tissues.html">
            http://www.cdc.gov/zika/laboratories/test-specimens-tissues.html</a>
        </li>
    </ul>
    <strong>Action needed: Zika virus disease is a nationally notifiable condition. Your patient meets criteria for
        reporting to the
        <a target="_blank" href="http://www.cdc.gov/zika/hc-providers/registry.html">US Zika Pregnancy Registry</a>.
    </strong> Report information about pregnant women with laboratory evidence of Zika virus to your state, tribal,
    local, or territorial health department.
    <ul>
        <li>
            If you are a healthcare provider or health department and you have questions about the registry, please
            <a href="mailto:ZikaMCH@cdc.gov">email</a> or call 770-488-7100 and ask for the Zika Pregnancy
            Hotline.
        </li>
    </ul>
</div>
<div id="igMTestReturn2to12Weeks">
    <strong>Action needed:</strong> Patient should return 2–12 weeks after possible Zika virus exposure for Zika virus
    IgM antibody testing. Because viral RNA in serum and urine declines over time and depends on multiple factors,
    asymptomatic pregnant women with a negative rRT-PCR result require additional testing to exclude infection.
    <ul>
        <li>
            ACOG recommends that when your patient returns 2-12 weeks after possible Zika virus exposure, you should
            store additional serum samples for further PRNT testing if needed.
        </li>
    </ul>
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
</div>
<div id="noEvidenceOfRecentZIKVInfection">
    <strong>Recommendations for clinical management:</strong>
    <ul>
        <li>
            Prenatal ultrasound to evaluate for fetal abnormalities consistent with congenital Zika virus syndrome.
            This includes microcephaly, intracranial calcifications, ventriculomegaly, arthrogryposis, and
            abnormalities of the corpus callosum, cerebrum, cerebellum, and eyes.
            <ul>
                <li>
                    If fetal abnormalities are present, repeat Zika virus rRT-PCR and IgM test; base clinical
                    management on corresponding laboratory results.
                </li>
                <li>
                    If fetal abnormalities are absent, base obstetric care on the ongoing risk of Zika virus
                    exposure in pregnant women.
                </li>
            </ul>
        </li>
    </ul>
</div>
<div id="armBReflexrRTPCR">
    <strong>Interpretation:</strong> At this point, interpretation of the testing results suggests presumptive recent
    Zika virus infection or presumptive recent flavivirus infection.
    <br /><br />
    <strong>Action needed:</strong> Reflex rRT-PCR testing should be automatically performed on the same serum sample
    and urine sample (if available) to determine whether Zika virus RNA is present. If your designated laboratory does
    not have capacity to perform reflex rRT-PCR testing, work with your health department or a commercial laboratory to
    submit a sample for further testing.
    <br /><br />
    <strong>Clinical management:</strong> For presumptive recent Zika virus infection or presumptive recent flavivirus
    infection, follow these <a href="#" onclick="event.preventDefault();
        nodeHistory.push(new NodeHistory(currentQuestionNumber, null));loadNode(36);">
        clinical management recommendations</a>.
    <br /><br />
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
    <br /><br />
    <strong>Follow-up action will be needed. Return to this tool for help interpreting the test results and determining if
        additional testing might be needed to confirm or rule out Zika virus infection. </strong>

</div>
<div id="clinicalManagementPresumptiveRecentZikaVirusInfectionOrRecentFlavivirusInfectionNOS">  <
    <strong>Interpretation of Test Result:</strong> Test results indicate presumptive recent Zika virus infection or
    recent maternal flavivirus infection, but the specific virus cannot be identified. For clinical management
    recommendations, answer <a href="#" onclick="event.preventDefault();
    nodeHistory.push(new NodeHistory(currentQuestionNumber, null));loadNode(37);"> this question</a>.
    <br /><br />
    <strong>Action needed: Zika virus disease is a nationally notifiable condition. Your patient meets criteria for
        reporting to the
        <a target="_blank" href="http://www.cdc.gov/zika/hc-providers/registry.html">US Zika Pregnancy Registry</a>.
    </strong> Report information about pregnant women with laboratory evidence of Zika virus to your state, tribal,
    local, or territorial health department.
    <ul>
        <li>
            If you are a healthcare provider or health department and you have questions about the registry, please
            <a href="mailto:ZikaMCH@cdc.gov">email</a> or call 770-488-7100 and ask for the Zika Pregnancy
            Hotline.
        </li>
    </ul>
</div>
<div id="prenatalClinicalManagementPresumptiveRecentZIKVInfectionOrFlavivirusNOS">
    <strong>Recommendations for prenatal management:</strong>
    <ul>
        <li>
            Consider serial ultrasounds <strong>every 3-4 weeks</strong> to assess fetal anatomy and growth. Fetal
            abnormalities consistent with congenital Zika virus syndrome include microcephaly, intracranial
            calcifications, vetriculomegaly, arthrogryposis, and abnormalities of the corpus callosum, cerebrum,
            cerebellum, and eyes.
        </li>
        <li>
            Amniocentesis might be considered. Decisions regarding amniocentesis should be individualized for each
            clinical circumstance.
        </li>
        <li>
            Notify state, tribal, local, or territorial health department staff or CDC registry staff of adverse
            events (e.g., birth defects, pregnancy losses).
        </li>
    </ul>
</div>
<div id="prnt">
    <strong>Interpretation:</strong> At this point, interpretation of the testing results suggest presumptive recent
    Zika virus infection or presumptive recent flavivirus infection.
    <br /><br />
    <strong>Action needed:</strong> Plaque reduction neutralization test (PRNT) against Zika and dengue viruses (or
    other flaviviruses endemic to the region where exposure occurred) should be automatically performed on the same
    IgM-tested sample or a subsequently collected sample. If your designated laboratory does not have capacity to
    perform PRNT, work with your health department to submit a sample for further testing.
    <br /><br />
    <strong>Clinical management:</strong> For presumptive recent Zika virus infection or presumptive recent flavivirus
    infection, follow these <a href="#" onclick="event.preventDefault();
        nodeHistory.push(new NodeHistory(currentQuestionNumber, null));loadNode(36);">
        clinical management recommendations</a>.
    <br /><br />
    <strong>To order test:</strong> Healthcare and laboratory professionals are instructed to direct Zika virus testing
    requests to their local or state public health laboratory or to a commercial laboratory that performs Zika testing
    using a validated assay with demonstrated analytical and clinical performance. Healthcare and laboratory
    professionals should follow state or local public health department guidance on notification procedures for suspect
    cases of Zika virus infection. For guidance on collecting and submitting body fluid specimens for Zika virus testing,
    visit <a target="_blank" href="http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html">CDC’s webpage</a>.
    <br /><br />
    <strong>Follow-up action will be needed. Return to this tool for help interpreting the test results and determine if
        additional testing might be needed to confirm or rule out Zika virus infection. </strong>
</div>
<div id="IngridsPaper">
    <strong>Interpretation:</strong> If you received PRNT results outside of the designated options, review this table
    for help interpreting the results. For more information, read
    <a target="_blank" href="http://www.cdc.gov/mmwr/volumes/65/wr/mm6521e1.htm?s_cid=mm6521e1_w">MMWR article</a> by
    Rabe et al.
    <br />
    <img src="img/IngridsTable.png" alt="TABLE Interpretation of results of antibody testing for suspected Zika virus
    infection - United States 2016.">
</div>